文献速递肾移植肾小球疾病

成人肾移植后FSGS复发:一项国际多中心队列研究

Recurrence of FSGS after Kidney Transplantation in Adults.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-01-23

TANGO项目是一项观察性国际多中心队列研究,筛查2005至2015年间肾移植受者,纳入176例特发性FSGS患者,发现32%复发,其中39%在 median 5年内失功;复发与首次肾病发病年龄较大、白人种族、移植时较低BMI及原生肾切除相关,血浆置换和利妥昔单抗为主要治疗,57%达到部分或完全缓解且与更好移植物存活相关。

要点

  • 特发性FSGS肾移植后复发率32%,复发者39%在中位5年内失功。
  • 复发预测因素包括首次肾病发病年龄较大、白人种族、移植时较低BMI及原生肾切除。
  • 血浆置换和利妥昔单抗为主要治疗,57%达到缓解,缓解与更好移植物存活相关。

核心结论

  • 特发性FSGS肾移植后约三分之一复发,复发与移植物丢失风险升高相关。
  • 治疗应答与显著更好的结局相关,但仅约半数患者达到缓解。

研究设计与样本

  • TANGO项目为观察性、多中心、国际队列研究,筛查2005至2015年间肾移植受者。
  • 11742例肾移植受者中176例诊断为特发性FSGS并纳入分析。

主要发现

  • 57例(32%;95% CI 25%至39%)发生FSGS复发,其中39%在中位5年(IQR 3.0-8.1)内失去移植物。
  • 多变量Cox回归显示首次肾病发病年龄较大与复发风险升高相关(HR 1.37/十年;95% CI 1.09至1.56)。
  • 其他预测因素包括白人种族(HR 2.14;95% CI 1.08至4.22)、移植时BMI(HR 0.89/kg/m2;95% CI 0.83至0.95)及原生肾切除(HR 2.76;95% CI 1.16至6.57)。
  • 血浆置换和利妥昔单抗是最常用治疗(81%),57%患者达到部分或完全缓解,且与更好的移植物存活相关。

临床怎么用

  • 对特发性FSGS肾移植受者应警惕复发,尤其具备发病年龄较大、白人种族、较低BMI或原生肾切除等特征者。
  • 复发后血浆置换和利妥昔单抗为常用治疗,达到缓解与更好移植物存活相关。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: FSGS recurrence after kidney transplantation is a major risk factor for graft loss. However, the natural history, clinical predictors, and response to treatment remain unclear because of small sample sizes and poor generalizability of single-center studies, and disease misclassification in registry-based studies. We therefore aimed to determine the incidence, predictors, and treatment response of recurrent FSGS in a large cohort of kidney transplant recipients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Post-Transplant Glomerular Disease (TANGO) project is an observational, multicenter, international cohort study that aims to investigate glomerular disease recurrence post-transplantation. Transplant recipients were screened for the diagnosis of idiopathic FSGS between 2005 and 2015 and details were recorded about the transplant, clinical outcomes, treatments, and other risk factors. RESULTS: Among 11,742 kidney transplant recipients screened for FSGS, 176 had a diagnosis of idiopathic FSGS and were included. FSGS recurred in 57 patients (32%; 95% confidence interval [95% CI], 25% to 39%) and 39% of them lost their graft over a median of 5 (interquartile range, 3.0-8.1) years. Multivariable Cox regression revealed a higher risk for recurrence with older age at native kidney disease onset (hazard ratio [HR], 1.37 per decade; 95% CI, 1.09 to 1.56). Other predictors were white race (HR, 2.14; 95% CI, 1.08 to 4.22), body mass index at transplant (HR, 0.89 per kg/m2; 95% CI, 0.83 to 0.95), and native kidney nephrectomies (HR, 2.76; 95% CI, 1.16 to 6.57). Plasmapheresis and rituximab were the most frequent treatments (81%). Partial or complete remission occurred in 57% of patients and was associated with better graft survival. CONCLUSIONS: Idiopathic FSGS recurs post-transplant in one third of cases and is associated with a five-fold higher risk of graft loss. Response to treatment is associated with significantly better outcomes but is achieved in only half of the cases.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Uffing A, Pérez-Sáez MJ, Mazzali M, et al. Recurrence of FSGS after Kidney Transplantation in Adults. Clin J Am Soc Nephrol. 2020. PMID: 31974287. doi:10.2215/CJN.08970719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。